Scholarlink

Purpose <p>Postsurgical pain (PSP) is a common complication in surgical patients that can progress to chronic pain and opioid dependence. Current analgesics, including opioids and non-opioid agents, are limited by short durations of action and adverse effects. This study reports the development and evaluation of extended-release bupivacaine microparticles (BuMPs) designed to provide sustained local analgesia and improve post-surgical pain management.</p> Methods <p>BuMPs were fabricated using PLGA and tested in a mouse sciatic nerve injury (SNI) model, a clinically relevant model of neuropathic pain. Mice received a single local injection of BuMPs or blank microparticles. Mechanical hypersensitivity was assessed using the von Frey test over a 21-day period. BuMPs were also compared to an FDA-approved liposomal bupivacaine formulation.</p> Results <p>We fabricated BuMPs by the hydrogel template method and confirmed their uniform size distribution. Thus prepared BuMPs exhibited extended bupivacaine release <i>in vitro</i> and <i>in vivo</i> in a healthy rat model. In a SNI model, BuMP-treated mice exhibited significantly reduced mechanical hypersensitivity compared to controls, with analgesic effects sustained for up to 21&#xa0;days. BuMPs provided prolonged pain relief, demonstrating effective modulation of postsurgical and neuropathic pain.</p> Conclusions <p>BuMPs offer a promising non-opioid strategy for long-acting PSP management. Their extended analgesic effect from a single perioperative injection may reduce opioid reliance, improve patient recovery, and serve as a complementary therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Local Delivery of Non-opioid Analgesic Microparticles to Modulate Post-surgical Pain

  • 期刊论文

  • 发表日期：

    2025年9月3日

查看全文
  • Prerna Mohan,
  • Jeladhara Sobhanan,
  • Caitlyn M. Gaffney,
  • Nitisha Mehrotra,
  • Fernando J. Cabrera,
  • Richard Lee,
  • Aparna Adumbumkulath,
  • Eric Haas,
  • Andrew J. Shepherd,
  • Crystal S. Shin,
  • Ghanashyam Acharya

摘要

Purpose

Postsurgical pain (PSP) is a common complication in surgical patients that can progress to chronic pain and opioid dependence. Current analgesics, including opioids and non-opioid agents, are limited by short durations of action and adverse effects. This study reports the development and evaluation of extended-release bupivacaine microparticles (BuMPs) designed to provide sustained local analgesia and improve post-surgical pain management.

Methods

BuMPs were fabricated using PLGA and tested in a mouse sciatic nerve injury (SNI) model, a clinically relevant model of neuropathic pain. Mice received a single local injection of BuMPs or blank microparticles. Mechanical hypersensitivity was assessed using the von Frey test over a 21-day period. BuMPs were also compared to an FDA-approved liposomal bupivacaine formulation.

Results

We fabricated BuMPs by the hydrogel template method and confirmed their uniform size distribution. Thus prepared BuMPs exhibited extended bupivacaine release in vitro and in vivo in a healthy rat model. In a SNI model, BuMP-treated mice exhibited significantly reduced mechanical hypersensitivity compared to controls, with analgesic effects sustained for up to 21 days. BuMPs provided prolonged pain relief, demonstrating effective modulation of postsurgical and neuropathic pain.

Conclusions

BuMPs offer a promising non-opioid strategy for long-acting PSP management. Their extended analgesic effect from a single perioperative injection may reduce opioid reliance, improve patient recovery, and serve as a complementary therapy.